This observational study evaluates the efficacy and safety of capecitabine in combination with oxaliplatin in the adjuvant setting in participants with Stage III colon cancer. Data were collected from each participant for up to 36 months or until disease recurrence.
Study Type
OBSERVATIONAL
Enrollment
74
Administered according to the Summary of Product Characteristics.
Administered according to the Summary of Product Characteristics.
Unnamed facility
Banská Bystrica, Slovakia
Unnamed facility
Bratislava, Slovakia
Unnamed facility
Bratislava, Slovakia
Unnamed facility
Košice, Slovakia
Disease-Free Survival (Time to Event)
Disease free survival was measured as the time from the date of randomization until the date of first event (recurrence of colon cancer, or death due to any cause).
Time frame: Up to 3 years
Safety: Percentage of Participants With Adverse Events
An adverse event is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events.
Time frame: Up to 3 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Unnamed facility
Martin, Slovakia
Unnamed facility
Nitra, Slovakia
Unnamed facility
Poprad, Slovakia
Unnamed facility
Prešov, Slovakia
Unnamed facility
Ružomberok, Slovakia